Welcome to our dedicated page for Aytu Biopharma news (Ticker: AYTU), a resource for investors and traders seeking the latest updates and insights on Aytu Biopharma stock.
Aytu BioPharma, Inc. develops and commercializes prescription medicines focused on complex central nervous system diseases. Its recurring company updates center on EXXUA (gepirone) extended-release tablets, an FDA-approved selective serotonin 5HT1a receptor agonist for major depressive disorder in adults, along with its ADHD products and legacy pediatric portfolio.
News from Aytu also covers operational and financial results, commercial launch activity, retail and Aytu RxConnect patient-access distribution, investor presentations, and product-level clinical and safety information for EXXUA. The company is a Nasdaq-listed specialty pharmaceutical issuer with prescription products sold through commercial distribution channels.
Aytu BioPharma (Nasdaq: AYTU), a pharmaceutical company focused on innovative medicines for complex central nervous system diseases, will participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026.
The virtual webcast begins at 9:15 a.m. ET, with replay available on the conference site and Aytu’s investor relations webpage. Management will also host virtual one-on-one meetings with investors during the event.
Aytu BioPharma (Nasdaq: AYTU) reported fiscal 2026 Q3 net revenue of $12.4 million, down from $18.5 million a year earlier, and a net loss of $5.6 million. Adjusted EBITDA was $(2.8) million.
EXXUA generated $2.4 million net revenue in its early launch, with more than 1,300 prescriptions from over 450 prescribers and over 3,200 units sold. ADHD and Pediatric portfolio revenues declined to $9.1 million and $0.9 million, respectively.
Gross profit was $7.6 million (61% margin). Cash was $26.7 million at March 31, 2026. A warrant amendment reduced derivative warrant liabilities by $26.4 million, increasing stockholders’ equity to $35.1 million.
Aytu BioPharma (Nasdaq: AYTU) will report operational and financial results for its fiscal 2026 third quarter after market close on Wednesday, May 13, 2026. A conference call and webcast to review results is scheduled the same day at 4:30 p.m. ET.
Dial-in access, a live webcast link, and a teleconference replay through May 27, 2026, are available for investors and analysts.
Aytu (Nasdaq: AYTU) reported Q2 fiscal 2026 net revenue of $15.2M, adjusted EBITDA of $(0.8)M, and a $30.0M cash balance at December 31, 2025. The company launched EXXUA (gepirone) in mid-December 2025 as its commercial centerpiece targeting the >$22B U.S. MDD market.
Q2 results included a $10.6M net loss (driven by an $8.2M derivative warrant liability loss), initial EXXUA stocking revenue of $0.2M, and gross margin of 63%.
Aytu BioPharma (Nasdaq: AYTU) will report its fiscal 2026 second quarter operational and financial results after market close on Tuesday, February 3, 2026. The company will host a conference call and live webcast the same day at 4:30 p.m. Eastern time followed by a Q&A session.
Call-in numbers: (888) 506-0062 (U.S.) and +1 (973) 528-0011 (international) using participant access code 567381. The webcast will be available live and archived at the provided webcast link and on the Investors section of the company website under Events & Presentations. A teleconference replay will be available through February 17, 2026 at (877) 481-4010 (U.S.) or +1 (919) 882-2331 (international) using replay access code 53322.
Aytu BioPharma (Nasdaq:AYTU) held Investor Day on January 20, 2026 focused on EXXUA (gepirone) ER, the first FDA‑approved 5HT1a agonist for major depressive disorder (MDD) that launched commercially on December 15, 2025. Management reviewed pivotal Phase 3 results showing statistically significant HAM‑D17 improvement versus placebo (placebo‑subtracted differences of −2.47 and −2.45 at Week 8) and safety data from ~1,976 MDD patients. Company highlighted market opportunity (US MDD market > $22B), full national distribution, early prescription uptake, expected EXXUA gross margin of 66–68%, and key commercialization economics including a 28% base royalty and upfront payments tied to Fabre‑Kramer agreement.
Aytu BioPharma (Nasdaq:AYTU) launched EXXUA (gepirone) nationwide on January 20, 2026, following completion of launch training. EXXUA is the first FDA‑approved selective 5‑HT1A agonist for treatment of major depressive disorder in adults and is available through retail and participating Aytu RxConnect pharmacies.
The company positions EXXUA as a once‑daily monotherapy that selectively targets 5‑HT1A receptors while minimizing activity at serotonin receptors tied to sexual dysfunction and weight gain, side effects that the release says commonly drive treatment discontinuation.
Aytu BioPharma (Nasdaq: AYTU) announced that CEO Josh Disbrow will participate in a fireside chat at the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 at 5:00 p.m. ET. The session is moderated by Thomas Flaten, senior research analyst at Lake Street Capital Markets.
The event will be available via webcast at https://lythampartners.com/hc2026/aytu and on the conference home page, with a replay accessible through the same links.
Aytu BioPharma (Nasdaq: AYTU) will hold an Investor Day on January 20, 2026 at 11:00 a.m. ET in New York City with a live webcast and archived replay available on the company's Investors site. The program will focus on EXXUA (gepirone) extended-release tablets, the first FDA-approved 5-HT1A agonist for major depressive disorder, and will feature presentations from KOLs and Aytu management followed by live Q&A.
In-person attendance requires advance registration via aytu@lythampartners.com.
Aytu BioPharma (Nasdaq: AYTU) will host an Investor Day on January 20, 2026 at 11:00 a.m. ET in New York City, featuring presentations from senior leadership and discussions with Key Opinion Leaders (KOLs) about EXXUA (gepirone) extended-release tablets.
EXXUA is described as the first FDA-approved 5HT1a agonist for major depressive disorder (MDD). Commercial availability of EXXUA commenced earlier this week. The event includes a live Q&A and a webcast; the live and archived presentation will be available on Aytu's Investors website under Events & Presentations. In-person attendance requires advance registration via Aytu Investor Relations (aytu@lythampartners.com).